Latest Breaking News On - Moleculin biotech inc - Page 38 : vimarsana.com

WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland s Share Capital

WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland s Share Capital
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaMariusz olejniczakMoleculin biotech incPharmaceuticals spBritish columbia newsfile corpWarsaw stock exchangeWake forest university health sciencesNeither the canadian securities exchangeInvestment industry regulatory organization of canadaPharmaceuticals incCompany board of directors theWake forest universityWall streetShareholder meetingWarsaw stock

WPD Pharmaceuticals Inc : WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland s Share Capital

Vancouver, British Columbia (Newsfile Corp. - September 20, 2022) - WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company announces that the

United kingdomBritish columbiaMariusz olejniczakMoleculin biotech incPharmaceuticals spBritish columbia newsfile corpWarsaw stock exchangeWake forest university health sciencesNeither the canadian securities exchangeInvestment industry regulatory organization of canadaPharmaceuticals incCompany board of directors theWake forest universityShareholder meetingWarsaw stockMoleculin biotech

Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesRobert shepardJenene thomasWalter klempRoswell park comprehensive cancer centerMoleculin biotech incExchange commissionOpportunities for international collaborations fundingMarie sklodowska curie symposium on cancer researchPreclinical research into clinical trialsSecurities exchangePrnewswire moleculin biotech incTranslational researchClinical developmentAnnual marie sklodowska curie symposiumCancer research

Moleculin to Present at the H C Wainwright 24th Annual Global Investment Conference

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

New yorkUnited statesJenene thomasWalter klempMoleculin biotech incMoleculin biotechChief executive officerAnnual global investment conferenceTranscription modulator

Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasWalter klempMoleculin biotech incDrug administrationExchange commissionSecurities exchangePrnewswire moleculin biotech incOrphan drug designationGlioblastoma multiformeChief executive officerInvestigational new drugMoleculin biotechTranscription modulatorSecurities actSecurities exchange act